Novo A/S becomes new long-term strategic shareholder in Evotec
Novo A/S invests EUR 90.3 m in new Evotec shares resulting in ownership of approx. 8.9% after the capital increase. Dr Werner Lanthaler, Chief Executive Officer of Evotec, commented: “We are delighted that Novo A/S, a highly regarded and well-known long-term investor has made this investment in Evotec.
This investment will allow us to accelerate our strategy to expand and invest in our best-in-class platform and outsourcing services and to build and invest in promising Cure X and Target X initiatives together with top academic partners and biotech globally.”